Comparative Pharmacology
Head-to-head clinical analysis: LIBRIUM versus LORAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRIUM versus LORAZ.
LIBRIUM vs LORAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, potentiating GABAergic inhibition and increasing chloride ion conductance.
Binds to gamma-aminobutyric acid (GABA) type A receptors at the benzodiazepine binding site, potentiating the effect of GABA, leading to increased chloride ion influx, neuronal hyperpolarization, and inhibition of neurotransmission.
5-25 mg orally 3-4 times daily; or 50-100 mg intramuscularly or intravenously initially, then 25-50 mg 3-4 times daily as needed.
2-6 mg orally or intravenously daily in divided doses; usual range 2-10 mg/day
None Documented
None Documented
Terminal elimination half-life of chlordiazepoxide is 24-48 hours; active metabolite desmethyldiazepam has half-life of 36-200 hours; with repeated dosing, effective half-life extends due to accumulation of active metabolites.
Clinical Note
moderateClorazepic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateTerminal elimination half-life: 12–15 hours in healthy adults. Extended in elderly (15–20 hours), hepatic impairment (up to 50 hours), and obesity.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates of chlordiazepoxide and demoxepam, <2% unchanged); approximately 60-70% of a dose appears in urine as metabolites, with 4-9% in feces via biliary elimination.
Renal: ~85% as glucuronide conjugates and ~10% as unchanged drug. Biliary/fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
Lorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."